Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Valerie Calvert et al.|Cancer Research|2022Cited by 160
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan‐Dagliyan, Channing J. Der, J. Nathaniel Diehl et al.|Cell Reports|2020Cited by 108
High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase InhibitorsJames J. Fiordalisi, Adrienne D. Cox|Journal of Biological Chemistry|2003Cited by 90
Src-Mediated Phosphorylation of the Tyrosine Phosphatase PRL-3 Is Required for PRL-3 Promotion of Rho Activation, Motility and InvasionJames J. Fiordalisi, Adrienne D. Cox|PLoS ONE|2013Cited by 38
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell CarcinomaSehrish Javaid, Adrienne D. Cox, Antje Schaefer et al.|Molecular Cancer Therapeutics|2022Cited by 18